查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1853734

呼吸道感染疾病診斷市場按技術、樣本類型、檢測方式、感染類型和最終用戶分類－全球預測，2025-2032年

Respiratory Infection Diagnostics Market by Technology, Sample Type, Test Mode, Infection Type, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，呼吸道感染疾病診斷市場規模將達到 1,454.4 億美元，複合年成長率為 7.36%。

關鍵市場統計數據
基準年 2024 823.5億美元
預計年份：2025年 883.8億美元
預測年份 2032 1454.4億美元
複合年成長率 (%) 7.36%

本文簡要介紹了臨床壓力、技術進步和不斷變化的診療路徑如何重新定義呼吸道感染疾病的診斷重點。

呼吸道感染疾病診斷在臨床護理、公共衛生和實驗室創新之間發揮核心作用。分子檢測、照護現場設備和數據整合技術的進步縮短了診斷週期，並將檢測範圍從中心實驗室擴展到醫院、診所和居家醫療。同時，近期疫情的爆發促使人們更加重視疾病監測，這促使支付方、醫療服務提供者和公共衛生機構重新評估診斷路徑及其在疫情防治和日常實踐中的作用。

臨床醫生日益要求診斷方法能夠在臨床相關的時間範圍內提供可操作的結果，而實驗室技術人員則優先考慮自動化和可重複性，以應對不斷波動的檢測量。製造商和解決方案供應商正透過整合平台、模組化耗材和軟體驅動的工作流程來應對這些需求，從而彌合實驗室檢測精度與即時檢測之間的差距。因此，策略性相關人員必須應對不斷變化的法律規範、供應鏈壓力和報銷預期，才能將技術能力轉化為持續的臨床應用。

技術、監管和數位化趨勢如何加速呼吸道感染疾病診斷解決方案的成熟和臨床應用

呼吸道感染疾病診斷正經歷多重變革，重塑產品開發、籌資策略和臨床工作流程。分子檢測已從高複雜度的實驗室檢測發展為精簡的床邊檢測平台，顯著縮短了檢測結果的獲取時間，並增強了針對特定病原體的管理。同時，定序技術也從專業研究工具轉變為可操作的臨床資源，能夠進行菌株鑑定和抗藥性監測，從而為治療和公共衛生應對措施提供資訊。

自動化和整合式樣本到結果系統正在降低對操作人員的依賴性，並支援醫院實驗室實現可擴展的檢測通量；同時，側向層析免疫測量和其他快速檢測方法不斷擴大分散式檢查的覆蓋範圍。主導的解讀和雲端資料聚合正開始將偵測結果與流行病學資訊連結起來，有助於及早發現新出現的叢集。監管機構也在不斷發展，日益支持緊急使用途徑和加速審查機制，同時強調上市後性能監測。這些轉變正在建立多模態診斷生態系統，其中商業性成功取決於互通性、資料完整性和供應鏈的穩定性。

評估新的關稅結構將如何重塑供應鏈、驅動籌資策略以及影響診斷試劑製造商和供應商的採購行為。

美國將於2025年實施累積關稅，這將對呼吸診斷產品的上游生產和下游臨床供應產生一系列複雜的壓力。進口零件和成品設備關稅的提高可能會增加依賴全球供應鏈獲取關鍵試劑、塑膠、墨盒和精密儀器組件的製造商的單位成本。這些成本壓力可能會擠壓製造商的利潤空間，促使他們重新談判供應商契約，並推動產品重新設計，優先考慮國內採購和零件標準化，以減輕關稅的影響。

對於臨床實驗室和即時檢測 (POC) 服務提供者而言，關稅導致的成本增加可能表現為設備購買價格上漲和耗材的持續支出增加。為因應此問題，採購團隊可能會延長設備更換週期、整合供應商，或優先選擇可降低單次診斷耗材消費量的多重偵測方法。同時，一些製造商可能會加快本地化生產或對替代供應商進行資格認證的策略步伐。這個過程雖然提高了供應的穩定性，但由於資格認證和監管檢驗的要求，也可能延長產品上市時間。

政策變化也將影響診斷研發公司的資本配置決策。投資者和企業決策者可能會重新評估其生產佈局，並考慮與契約製造製造商採用聯合投資模式，以分散關稅風險。公共機構負責人和醫院網路可以利用其購買力，協商分級定價和長期供應協議，從而穩定下游成本。最終，關稅環境凸顯了供應鏈透明度、組件可追溯性和靈活籌資策略的重要性，這些策略需要在短期成本影響與長期可靠性和臨床連續性之間取得平衡。

詳細的細分洞察揭示了技術、樣本類型、檢測模式、感染重點和最終用戶動態如何獨特地塑造產品需求和採用路徑。

詳細的市場區隔分析揭示了不同技術和應用場景如何推動差異化的應用和創新。從技術角度來看，酵素結合免疫吸附檢測法（ELISA）和側向流動免疫檢測分析等免疫檢測檢測方法分別在高通量篩檢和分散式快速檢測中發揮重要作用；微生物培養仍然是生物分離的參考方法，與傳統的手工培養相比，自動化培養系統提高了周轉時間和重複性。分子診斷包括成熟的聚合酵素鏈鎖反應（PCR）工作流程和恒溫環型核酸擴增）等等溫擴增技術，這些技術因其更快更便捷的核酸檢測而日益普及；而次世代定序）和桑格定序等定序技術則在監測、抗藥性分析和研究應用中發揮著補充作用。

就樣本類型而言，血液檢測可提供血清學結果和系統性標記物，而鼻咽拭子是呼吸道病原體檢測的主要檢體，其採集和處理流程已較為成熟。唾液是一種極具吸引力的非侵入性替代方案，可降低採集風險並提高患者接受度，而痰液對於下呼吸道感染疾病仍然十分重要，因為病原體載量和檢體質量會影響診斷率。檢測模式分為兩類：一類是實驗室平台，其優先考慮多重檢測的深度和靈敏度；另一類是即時檢測系統，其強調速度、易用性和分散式訪問，這導致了不同的應用促進因素和報銷模式。

冠狀病毒疾病診斷推動了對快速多重檢測和基因組監測的投資；流感診斷受益於季節性防治週期和抗病毒藥物管理計劃；呼吸道融合細胞病毒檢測在兒科和老年護理路徑中的作用日益受到重視。最後，終端使用者細分顯示，診所和醫院正在尋求適合臨床決策的整合工作流程和符合監管要求的平台；居家醫療機構正在尋求簡化易用的儀器和清晰的結果解讀；而研究實驗室則優先考慮靈活性、通量和深度分析能力，以進行探索性和檢驗研究。

區域監管差異、基礎設施成熟度和製造能力將如何決定全球市場的採用模式和商業策略

區域動態對診斷創新、應用和商業化策略有顯著影響。在美洲，完善的檢測基礎設施、集中的公共衛生網路和龐大的私人醫療保健系統為高通量檢測平台和即時檢測解決方案的快速普及提供了支援。該地區的監管事務著重於臨床表現和品質體系，而報銷體系則獎勵那些能夠顯著改善臨床決策並降低後續成本的診斷方法。

在歐洲、中東和非洲，醫療服務體系和監管成熟度的差異導致了檢測技術應用環境的多樣性。該地區的高所得市場往往率先採用先進的分子檢測和定序，而新興市場則優先考慮成本效益高的快速檢測方法和維護成本低的設備。跨境公共衛生協調和區域採購機制可以放大對標準化檢測的需求，製造商也經常根據不同的基礎設施和物流調整其檢測產品。

亞太市場涵蓋了各種不同的市場能力，既有先進、創新主導、擁有強大國內製造業和快速法規核准能力的市場，也有資源匱乏、優先考慮價格可負擔性和供應安全的市場。在一些國家，國內製造業能力支撐著具有競爭力的價格和較短的前置作業時間週期，而公共衛生優先事項和龐大的人口基數則推動了對監測和可擴展診斷部署的投資。在每個地區，互通性、低溫運輸物流和與當地監管機構的合作都是成功實現商業化的關鍵要素。

呼吸診斷領域領導地位的形成，以及商業性優勢能否持續，取決於競爭、協作和營運等因素。

呼吸系統診斷領域的競爭格局正因技術差異化、策略夥伴關係和規模化三者共同作用而重塑。投資於整合解決方案的公司，若能將靈敏的檢測化學技術與無縫的儀器設計和直覺的軟體介面相結合，將在臨床應用方面佔據優勢。同時，診斷試劑開發商、儀器製造商和契約製造製造商之間的合作，能夠在保持檢測方法開發和品管方面專業技術的同時，實現快速擴大生產規模。

除了垂直整合的趨勢外，圍繞檢測化學、試劑盒設計和雲端基礎分析的智慧財產權對國防領域的重要性也日益凸顯。能夠開發出展現臨床效用和衛生經濟價值的可靠證據包的公司，可以加強與醫院和支付方的合作關係。包含遠端監測、試劑補充和運作保證在內的服務模式，能夠帶來持續的收入來源，並深化客戶關係。最後，與公共衛生機構和醫院網路進行策略合作、試點監測計畫以及整合舉措，能夠使公司在常規季節性疫情和突發事件應變中都成為值得信賴的合作夥伴。

診斷試劑開發人員和供應商可以實施哪些切實可行的策略措施和營運重點，以增強呼吸系統檢測的韌性、普及率和長期發展？

產業領導者應採取一系列策略行動，以平衡短期韌性和長期創新。首先，透過對關鍵試劑和耗材的多家供應商進行資格認證，實現供應鏈多元化；並在經濟可行的情況下投資本地生產能力，以降低關稅和物流成本。其次，優先考慮模組化平台設計，以便在不更換整台儀器的情況下進行檢測升級；並投資於試劑盒和耗材的標準化，以簡化採購流程。

第三，我們將從研發初期就加強與監管機構和支付方的合作，以累積證據，並與臨床決策閾值和報銷標準保持一致。第四，我們將加快與臨床網路和公共衛生組織的合作，以檢驗產品在實際應用中的效能，並獲得早期用戶的認可，從而支持規模化生產。第五，我們將拓展數位化能力，例如雲端基礎的彙報、遠端設備監控和人工智慧驅動的結果解讀，以增強差異化優勢，並提供能夠支撐更高價格分佈的附加價值服務。最後，我們將保持嚴謹的情境規劃，並對我們的產能和銷售模式進行壓力測試，以確保在面對價格波動、需求激增和其他干擾因素時，業務永續營運。

採用嚴謹的混合方法，整契約儕審查的證據、監管指南和相關人員訪談，以檢驗診斷市場和商業洞察。

本報告的研究結合了結構化的二手資料研究和重點突出的一手資料研究，以確保得出平衡且有效的結論。二級資訊來源包括同行評審文獻、監管指導文件、臨床實踐指南和開放原始碼政策分析，旨在建立事實基礎，並將技術能力與已知的法律規範相匹配。這些資訊來源為關於技術採納促進因素、臨床效用以及區域監管差異的初步假設提供了基礎。

主要研究包括對相關人員的訪談，包括臨床實驗室技術人員、感染疾病專家、採購負責人、生產專家和監管專家。這些訪談的見解用於檢驗次要研究結果，揭示營運方面的限制因素，例如供應鏈脆弱性和勞動力不足，並了解從業人員對速度、靈敏度和成本之間權衡的觀點。數據綜合採用了跨資訊來源的三角驗證和迭代檢驗，以確保盡可能在結論中體現共識，並將分歧領域透明地報告出來。調查方法的限制包括政策和關稅環境的變化，以及供應商特定數據的差異。

綜合各項可操作的結論，強調呼吸系統診斷領域取得持久成功所需的韌性、主導應用和策略合作。

越來越多的分析表明，呼吸道感染疾病診斷正進入一個以技術融合、對快速、可操作結果的期望不斷提高以及供應鏈日益複雜為特徵的階段。那些在平台設計和籌資策略都優先考慮靈活性的相關人員，將更有可能應對關稅相關的成本壓力和不斷變化的採購重點。同時，對數據整合和證據產生的投資對於說服臨床醫生和支付方認知到診斷的價值至關重要，並能使他們在治療決策和公共衛生監測中發揮核心作用。

總之，實現持續商業性成功的關鍵在於將強大的檢測性能、營運韌性、監管前瞻性以及清晰的臨床效用價值相結合。能夠協調產品開發與終端用戶工作流程、儘早與監管機構和支付相關人員溝通並建立適應性強的供應鏈的舉措，不僅能夠更好地抵禦短期衝擊，還能充分利用市場對快速、可靠的呼吸系統診斷日益成長的需求。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 擴展多重PCR平台以實現多種呼吸道病原體的同時檢測
  • 加強雲端基礎的數據分析在呼吸道感染疾病疫情即時監測的應用
  • 基於 CRISPR 的診斷技術能夠在臨床環境中實現對呼吸道病毒的超靈敏檢測。
  • 在呼吸道疾病流行季節，用於區分新冠病毒、流感和呼吸道融合病毒（RSV）的多重抗原檢測的需求增加。
  • 利用可攜式等溫擴增技術和橫向流動化驗方法推進分散式檢查舉措
  • 重點研究並開發宿主生物標記檢測方法，以區分嚴重呼吸道疾病治療中的細菌合併感染。
  • 採用次世代定序工作流程進行全面的呼吸道病原體分析和突變監測
  • 診斷公司與遠端醫療平台建立策略夥伴關係，以擴大遠距呼吸道傳染病檢查服務
  • 監管部門的核准加速了新型即時分子檢測技術進入市場，該技術可快速識別呼吸道病毒。
  • 投資人工智慧驅動的模式識別工具，以根據診斷和臨床數據預測呼吸道感染疾病趨勢。

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 按技術分類的呼吸道感染疾病診斷市場

  • 免疫檢測
    • 酵素結合免疫吸附試驗
    • 側向流動免疫檢測
  • 微生物培養
    • 自動化培養系統
    • 傳統文化
  • 分子診斷
    • 環介導等溫擴增
    • 聚合酵素鏈鎖反應
  • 定序
    • 次世代定序
    • 桑格定序

9. 呼吸道感染疾病診斷市場（依樣本類型分類）

  • 血
  • 鼻拭子
  • 唾液
  • 痰
  • 咽拭子

第10章 呼吸道感染疾病診斷市場：檢測模式

  • 實驗室
  • POC

第11章 依感染類型分類的呼吸道感染疾病診斷市場

  • 2019冠狀病毒感染疾病
  • 流感
  • 呼吸道融合病毒（RSV）

第12章 依最終用戶分類的呼吸道感染疾病診斷市場

  • 診所
  • 居家照護
  • 醫院
  • 研究所

第13章 各地區呼吸道感染疾病診斷市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 呼吸道感染疾病診斷市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國呼吸道感染疾病診斷市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • F. Hoffmann-La Roche AG
    • Danaher Corporation
    • Thermo Fisher Scientific Inc.
    • Abbott Laboratories
    • Siemens Healthineers AG
    • bioMerieux SA
    • Hologic Inc.
    • QIAGEN NV
    • Quidel Corporation
    • Becton, Dickinson and Company
Product Code: MRR-02026C4C8612

The Respiratory Infection Diagnostics Market is projected to grow by USD 145.44 billion at a CAGR of 7.36% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 82.35 billion
Estimated Year [2025] USD 88.38 billion
Forecast Year [2032] USD 145.44 billion
CAGR (%) 7.36%

A concise primer on how clinical pressures, technological advances, and care pathway shifts are redefining respiratory infection diagnostic priorities

Respiratory infection diagnostics occupy a central role at the intersection of clinical care, public health, and laboratory innovation. Advances in molecular detection, point-of-care instrumentation, and data integration have accelerated diagnostic turnaround times and expanded testing beyond centralized laboratories into hospitals, clinics, and home care settings. Simultaneously, heightened awareness of disease surveillance following recent pandemic events has pushed payers, providers, and public health agencies to reassess diagnostic pathways and their role in outbreak preparedness and routine care.

Clinicians increasingly demand diagnostics that deliver actionable results within clinically relevant windows, while laboratorians prioritize automation and reproducibility to manage fluctuating test volumes. Manufacturers and solution providers are responding with integrated platforms, modular consumables, and software-enabled workflows that bridge the gap between laboratory accuracy and point-of-care accessibility. Consequently, strategic stakeholders must navigate evolving regulatory frameworks, supply chain pressures, and shifting reimbursement expectations to translate technical capability into sustained clinical adoption.

How converging technological, regulatory, and digital trends are accelerating the maturation and clinical integration of respiratory infection diagnostic solutions

The respiratory diagnostics landscape is experiencing multiple transformative shifts that are reshaping product development, procurement strategies, and clinical workflows. Molecular methods have matured from high-complexity laboratory assays to streamlined, near-patient platforms that reduce time-to-result and enhance pathogen-specific management. At the same time, sequencing technologies have transitioned from specialized research tools into actionable clinical assets, enabling lineage identification and resistance surveillance that inform treatment and public health responses.

Automation and integrated sample-to-answer systems are reducing operator dependence and supporting scalable throughput in hospital laboratories, whereas lateral flow immunoassays and other rapid formats continue to expand accessibility for decentralized testing. AI-driven interpretation and cloud-enabled data aggregation are beginning to connect test results with epidemiologic intelligence, facilitating earlier detection of emerging clusters. Regulatory bodies have also evolved, increasingly accommodating emergency use pathways and accelerated review mechanisms while emphasizing post-market performance monitoring. Together, these shifts are creating a multi-modal diagnostic ecosystem where interoperability, data integrity, and supply resilience determine commercial success.

Assessment of how new tariff structures reshape supply chains, drive sourcing strategies, and influence procurement behavior across diagnostic manufacturers and providers

The introduction of cumulative United States tariffs in 2025 introduces a complex set of pressures that affect both upstream manufacturing and downstream clinical delivery of respiratory diagnostics. Increased duties on imported components and finished instruments can elevate per-unit costs for manufacturers that rely on global supply chains for critical reagents, plasticware, cartridges, and precision instrument parts. These cost pressures may compress manufacturer margins, prompt renegotiation of supplier contracts, and incentivize redesigns that prioritize domestic sourcing or component standardization to mitigate tariff exposure.

For clinical laboratories and point-of-care operators, tariff-driven cost increases can manifest as higher acquisition prices for instruments and recurring expenditures for consumables. In response, procurement teams may extend device replacement cycles, consolidate suppliers, or prioritize multiplexed assays that reduce per-diagnosis consumable consumption. Simultaneously, some manufacturers may accelerate strategic moves to localize manufacturing or qualify alternative suppliers, a process that improves supply resilience but can lengthen time-to-market due to qualification and regulatory validation requirements.

Policy-induced shifts also influence capital allocation decisions among diagnostic developers. Investors and corporate decision-makers may reassess manufacturing footprints and consider co-investment models with contract manufacturers to spread tariff exposure. Public-sector purchasers and hospital networks could use buying power to negotiate tiered pricing or long-term supply agreements that stabilize downstream costs. Ultimately, the tariff environment reinforces the importance of supply chain transparency, component traceability, and agile sourcing strategies that balance near-term cost impacts with long-term reliability and clinical continuity.

Detailed segmentation insights revealing how technology, sample type, test mode, infection focus, and end-user dynamics uniquely shape product demand and adoption pathways

A granular view of the market segmentation highlights how distinct technologies and use contexts are driving differential adoption and innovation. Based on technology, immunoassay formats such as enzyme linked immunosorbent assays and lateral flow immunoassays remain crucial for high-throughput screening and decentralized rapid testing respectively, whereas microbiological culture methods continue to serve as the reference for organism isolation with automated culture systems improving turnaround and reproducibility compared with conventional manual culture. Molecular diagnostics encompass established polymerase chain reaction workflows and isothermal approaches such as loop mediated isothermal amplification that are gaining traction for faster, simpler nucleic acid detection, while sequencing techniques including next generation sequencing and Sanger sequencing offer complementary roles in surveillance, resistance profiling, and research applications.

When considering sample types, blood-based assays provide serologic insight and systemic markers, nasal swabs and throat swabs are primary specimen types for respiratory pathogen detection with well-established collection and handling workflows, saliva presents an attractive non-invasive alternative that reduces collection risk and improves patient acceptance, and sputum remains important for lower respiratory infections where pathogen load and specimen quality affect diagnostic yield. Test modes separate laboratory-based platforms that prioritize depth of multiplexing and sensitivity from point-of-care systems that emphasize speed, ease of use, and decentralized access, creating different adoption drivers and reimbursement models.

Infection type segmentation emphasizes that solutions tailored to coronavirus disease, influenza, and respiratory syncytial virus each face unique clinical prioritization; coronavirus disease diagnostics have driven investment in rapid multiplexing and genomic surveillance, influenza diagnostics benefit from seasonal preparedness cycles and antiviral stewardship programs, and respiratory syncytial virus testing is increasingly recognized for its role in pediatric and geriatric care pathways. Finally, end-user segmentation shows that clinics and hospitals demand integrated workflows and regulatory-compliant platforms suited to clinical decision-making, home care settings require simplified, user-friendly devices and clear result interpretation, and research laboratories prioritize flexibility, throughput, and deep analytical capabilities for exploratory and validation studies.

How regional regulatory diversity, infrastructure maturity, and manufacturing capacity drive divergent adoption patterns and commercial strategies across global markets

Regional dynamics exert a powerful influence on diagnostic innovation, adoption, and commercialization strategies. In the Americas, robust laboratory infrastructure, centralized public health networks, and large private healthcare systems support rapid uptake of both high-throughput laboratory platforms and point-of-care solutions. Regulatory pathways in this region emphasize clinical performance and quality systems, and reimbursement dynamics can reward diagnostics that demonstrably improve clinical decision-making and reduce downstream costs.

Across Europe, the Middle East, and Africa, heterogeneity in healthcare delivery and regulatory maturity creates a patchwork of adoption environments. High-income markets within the region often lead in advanced molecular and sequencing adoption, while emerging markets prioritize cost-effective rapid tests and instruments with low maintenance requirements. Cross-border public health coordination and regional procurement mechanisms can amplify demand for standardized assays, and manufacturers often tailor offerings to meet diverse infrastructure and logistics constraints.

Asia-Pacific markets demonstrate a spectrum of capability from advanced, innovation-driven markets with strong domestic manufacturing and rapid regulatory review to lower-resource settings that value affordability and supply stability. Domestic manufacturing capacity in several countries supports competitive pricing and shorter lead times, while public health priorities and large population bases drive investment in surveillance and scalable diagnostics deployment. Across regions, interoperability, cold chain logistics, and local regulatory engagement remain critical determinants of successful commercialization.

Competitive, collaborative, and operational forces that define leadership in the respiratory diagnostics sector and determine the durability of commercial advantage

Competitive landscapes in respiratory diagnostics are being reshaped by a combination of technological differentiation, strategic partnerships, and operational scale. Companies that invest in integrated solutions that combine sensitive detection chemistries with seamless instrument design and intuitive software interfaces gain advantages in clinical adoption. Meanwhile, alliances between diagnostic developers, instrument manufacturers, and contract manufacturers enable faster scale-up of production while preserving specialized expertise in assay development and quality control.

In addition to vertical integration moves, intellectual property around assay chemistries, cartridge designs, and cloud-based analytics is increasingly important for defensibility. Firms that develop robust evidence packages demonstrating clinical utility and health-economic value secure stronger hospital and payer engagement. Service models that include remote monitoring, reagent replenishment, and uptime guarantees create recurring revenue streams and deepen client relationships. Finally, strategic collaborations with public health agencies and hospital networks to pilot surveillance initiatives and integrate reporting can position companies as trusted partners during both routine seasons and outbreak response scenarios.

Practical strategic measures and operational priorities that diagnostic developers and providers can implement to strengthen resilience, adoption, and long-term growth in respiratory testing

Industry leaders should adopt a portfolio of strategic actions that balance near-term resilience with long-term innovation. First, diversify supply chains by qualifying multiple suppliers for critical reagents and consumables and by investing in localized manufacturing capacity where economically feasible to reduce tariff and logistics exposure. Second, prioritize modular platform designs that allow assay updates without full instrument replacement and invest in cartridge or consumable standardization to simplify procurement for buyers.

Third, strengthen regulatory and payer engagement early in development to align evidence generation with clinical decision thresholds and reimbursement criteria. Fourth, accelerate partnerships with clinical networks and public health entities to validate real-world performance and to secure early-adopter references that support scale-up. Fifth, expand digital capabilities, including cloud-based reporting, remote device monitoring, and AI-enabled result interpretation, to enhance differentiation and to provide value-added services that justify higher price points. Finally, maintain disciplined scenario planning and stress-testing of capacity and distribution models to ensure operational continuity under tariff shifts, demand surges, and other disruptions.

A rigorous mixed-methods approach that integrates peer-reviewed evidence, regulatory guidance, and stakeholder interviews to validate diagnostic market and operational insights

The research underlying this report combines structured secondary research with targeted primary engagement to ensure balanced, validated insight. Secondary sources included peer-reviewed literature, regulatory guidance documents, clinical practice guidelines, and open-source policy analyses to create a foundation of factual context and to map technological capabilities and known regulatory frameworks. These sources informed initial hypotheses concerning technology adoption drivers, clinical utility, and regional regulatory variation.

Primary research consisted of interviews with a cross-section of stakeholders including clinical laboratorians, infectious disease specialists, procurement leaders, manufacturing experts, and regulatory professionals. Insights from these conversations were used to validate secondary findings, to surface operational constraints such as supply chain fragility and workforce limitations, and to capture practitioner perspectives on trade-offs between speed, sensitivity, and cost. Data synthesis incorporated triangulation across sources and iterative validation to ensure that conclusions reflect consensus where possible and transparently report areas of divergence. Limitations of the methodology include the evolving nature of policy and tariff environments and the variability of proprietary supplier data; readers are advised to consider these dynamics when applying findings to specific commercial decisions.

Synthesis of actionable conclusions emphasizing resilience, evidence-driven adoption, and the strategic alignment required for enduring success in respiratory diagnostics

The cumulative analysis underscores that respiratory infection diagnostics are entering a phase defined by technological convergence, heightened expectations for rapid actionable results, and increasing supply chain complexity. Stakeholders who prioritize flexibility-both in platform design and in sourcing strategies-will be better positioned to navigate tariff-related cost pressures and shifting procurement priorities. At the same time, investments in data integration and evidence generation will be pivotal for convincing clinicians and payers of diagnostic value and for enabling diagnostics to play a central role in therapeutic decision-making and public health surveillance.

In sum, the pathway to durable commercial success blends robust assay performance with operational resilience, regulatory foresight, and a clear articulation of clinical utility. Organizations that align product development with end-user workflows, engage early with regulatory and payer stakeholders, and build adaptable supply chains will not only withstand near-term disruptions but also capitalize on the growing demand for rapid, reliable respiratory diagnostics.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Expansion of multiplex PCR platforms enabling simultaneous detection of multiple respiratory pathogens
  • 5.2. Increasing integration of cloud-based data analytics to monitor respiratory infection outbreaks in real time
  • 5.3. Emergence of CRISPR-based diagnostics for ultra-sensitive detection of emerging respiratory viruses at point of care
  • 5.4. Rising demand for multiplex antigen testing to differentiate between COVID-19 influenza and RSV during respiratory season
  • 5.5. Growth of decentralized testing initiatives driven by portable isothermal amplification technologies and lateral flow assays
  • 5.6. R&D focus on host biomarker assays to distinguish bacterial coinfections in severe respiratory disease management
  • 5.7. Adoption of next-generation sequencing workflows for comprehensive respiratory pathogen profiling and variant surveillance
  • 5.8. Strategic partnerships between diagnostic firms and telehealth platforms to expand remote respiratory infection testing services
  • 5.9. Regulatory approvals accelerating market entry of novel point-of-care molecular tests for rapid respiratory virus identification
  • 5.10. Investment in AI-powered pattern recognition tools to predict respiratory infection trends from diagnostic and clinical data

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Respiratory Infection Diagnostics Market, by Technology

  • 8.1. Immunoassay
    • 8.1.1. Enzyme Linked Immunosorbent Assay
    • 8.1.2. Lateral Flow Immunoassay
  • 8.2. Microbiological Culture
    • 8.2.1. Automated Culture Systems
    • 8.2.2. Conventional Culture
  • 8.3. Molecular Diagnostics
    • 8.3.1. Loop Mediated Isothermal Amplification
    • 8.3.2. Polymerase Chain Reaction
  • 8.4. Sequencing
    • 8.4.1. Next Generation Sequencing
    • 8.4.2. Sanger Sequencing

9. Respiratory Infection Diagnostics Market, by Sample Type

  • 9.1. Blood
  • 9.2. Nasal Swab
  • 9.3. Saliva
  • 9.4. Sputum
  • 9.5. Throat Swab

10. Respiratory Infection Diagnostics Market, by Test Mode

  • 10.1. Laboratory Based
  • 10.2. Point Of Care

11. Respiratory Infection Diagnostics Market, by Infection Type

  • 11.1. Coronavirus Disease
  • 11.2. Influenza
  • 11.3. Respiratory Syncytial Virus

12. Respiratory Infection Diagnostics Market, by End User

  • 12.1. Clinics
  • 12.2. Home Care Settings
  • 12.3. Hospitals
  • 12.4. Research Laboratories

13. Respiratory Infection Diagnostics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Respiratory Infection Diagnostics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Respiratory Infection Diagnostics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. F. Hoffmann-La Roche AG
    • 16.3.2. Danaher Corporation
    • 16.3.3. Thermo Fisher Scientific Inc.
    • 16.3.4. Abbott Laboratories
    • 16.3.5. Siemens Healthineers AG
    • 16.3.6. bioMerieux SA
    • 16.3.7. Hologic Inc.
    • 16.3.8. QIAGEN N.V.
    • 16.3.9. Quidel Corporation
    • 16.3.10. Becton, Dickinson and Company

LIST OF FIGURES

  • FIGURE 1. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST MODE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST MODE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY INFECTION TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY INFECTION TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. RESPIRATORY INFECTION DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. RESPIRATORY INFECTION DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. RESPIRATORY INFECTION DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGICAL CULTURE, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGICAL CULTURE, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGICAL CULTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGICAL CULTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGICAL CULTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGICAL CULTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGICAL CULTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGICAL CULTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY AUTOMATED CULTURE SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY AUTOMATED CULTURE SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY AUTOMATED CULTURE SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY AUTOMATED CULTURE SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY AUTOMATED CULTURE SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY AUTOMATED CULTURE SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CONVENTIONAL CULTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CONVENTIONAL CULTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CONVENTIONAL CULTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CONVENTIONAL CULTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CONVENTIONAL CULTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CONVENTIONAL CULTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY LOOP MEDIATED ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY LOOP MEDIATED ISOTHERMAL AMPLIFICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY LOOP MEDIATED ISOTHERMAL AMPLIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY LOOP MEDIATED ISOTHERMAL AMPLIFICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY LOOP MEDIATED ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY LOOP MEDIATED ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SANGER SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SANGER SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SANGER SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SANGER SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY BLOOD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY BLOOD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY BLOOD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY BLOOD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY BLOOD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY NASAL SWAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY NASAL SWAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY NASAL SWAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY NASAL SWAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY NASAL SWAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY NASAL SWAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SALIVA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SALIVA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SALIVA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SALIVA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SALIVA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SALIVA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SPUTUM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SPUTUM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SPUTUM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SPUTUM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SPUTUM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SPUTUM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY THROAT SWAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY THROAT SWAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY THROAT SWAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY THROAT SWAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY THROAT SWAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY THROAT SWAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST MODE, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST MODE, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY LABORATORY BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY LABORATORY BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY LABORATORY BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY LABORATORY BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY LABORATORY BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY LABORATORY BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY POINT OF CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY POINT OF CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY POINT OF CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY POINT OF CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY POINT OF CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY POINT OF CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY INFECTION TYPE, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CORONAVIRUS DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CORONAVIRUS DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CORONAVIRUS DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CORONAVIRUS DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CORONAVIRUS DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CORONAVIRUS DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY INFLUENZA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY INFLUENZA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY INFLUENZA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY INFLUENZA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY INFLUENZA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 183. AMERICAS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 185. AMERICAS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 186. AMERICAS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 187. AMERICAS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGICAL CULTURE, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGICAL CULTURE, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST MODE, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST MODE, 2025-2032 (USD MILLION)
  • TABLE 197. AMERICAS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY INFECTION TYPE, 2025-2032 (USD MILLION)
  • TABLE 199. AMERICAS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. NORTH AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 204. NORTH AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 206. NORTH AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGICAL CULTURE, 2018-2024 (USD MILLION)
  • TABLE 208. NORTH AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGICAL CULTURE, 2025-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 210. NORTH AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST MODE, 2018-2024 (USD MILLION)
  • TABLE 216. NORTH AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST MODE, 2025-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 218. NORTH AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY INFECTION TYPE, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. LATIN AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 224. LATIN AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 226. LATIN AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGICAL CULTURE, 2018-2024 (USD MILLION)
  • TABLE 228. LATIN AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGICAL CULTURE, 2025-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 230. LATIN AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 232. LATIN AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 234. LATIN AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST MODE, 2018-2024 (USD MILLION)
  • TABLE 236. LATIN AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST MODE, 2025-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. LATIN AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY INFECTION TYPE, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGICAL CULTURE, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGICAL CULTURE, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST MODE, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST MODE, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY INFECTION TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGICAL CULTURE, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGICAL CULTURE, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST MODE, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST MODE, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY INFECTION TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE RESPIRATORY INFECTION DIAGNOSTIC